Neal Yuan1, Rebecca Scherzer, Kahraman Tanriverdi, Jeffrey Martin, Smruti Rahalkar, Priscilla Hsue. 1. aDepartment of Medicine, University of California, San Francisco bDepartment of Medicine, Veteran's Affairs Medical Center, San Francisco, University of California, San Francisco, California cDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts dDepartment of Epidemiology and Biostatistics, University of California San Francisco and San Francisco General Hospital HIV/AIDS Division eDivision of Cardiology, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA.
Abstract
OBJECTIVE: Individuals with HIV suffer a higher burden of cardiovascular diseases. Traditional cardiovascular risk scores consistently underestimate cardiovascular risk in this population. Subsets of microRNAs (miRNAs) are differentially expressed among individuals with cardiovascular disease and individuals infected with HIV. However, no study has clarified whether specific miRNAs may be biomarkers for cardiovascular disease in individuals with HIV. DESIGN/ METHODS: We compared the miRNA expression profiles of 34 HIV-positive individuals who had experienced clinically adjudicated type I myocardial infarctions (MI) with the profiles of 76 HIV-positive controls matched by traditional cardiovascular risk factors and HIV-specific measures. Using the elastic net algorithm, we selected miRNAs most strongly associated with incident MI and then used conditional Cox proportional hazards regression and cross-validation to evaluate miRNAs and their association with incident MI. We evaluated whether miRNA markers would improve risk classification relative to the Framingham Risk Score. RESULTS: Higher miR-125a-5p and miR-139-5p expression levels were each associated with increased risk of developing MI after adjustment for Framingham Risk Score and HIV-related factors (hazard ratio 2.43, P = 0.018; hazard ratio 2.13, P = 0.048, respectively). Compared with the Framingham Risk Score alone, adding expression levels of miR-125a-5p or miR-139-5p resulted in an integrated discrimination improvement of 10.1 or 5.8%, respectively. CONCLUSION: MiR-125a-5p and miR-139-5p, transcripts known to be differentially expressed in HIV-positive individuals, may serve as unique biomarkers predictive of cardiovascular disease in these patients and may help clarify processes because of HIV infection that contribute to cardiovascular disorders in this population.
OBJECTIVE: Individuals with HIV suffer a higher burden of cardiovascular diseases. Traditional cardiovascular risk scores consistently underestimate cardiovascular risk in this population. Subsets of microRNAs (miRNAs) are differentially expressed among individuals with cardiovascular disease and individuals infected with HIV. However, no study has clarified whether specific miRNAs may be biomarkers for cardiovascular disease in individuals with HIV. DESIGN/ METHODS: We compared the miRNA expression profiles of 34 HIV-positive individuals who had experienced clinically adjudicated type I myocardial infarctions (MI) with the profiles of 76 HIV-positive controls matched by traditional cardiovascular risk factors and HIV-specific measures. Using the elastic net algorithm, we selected miRNAs most strongly associated with incident MI and then used conditional Cox proportional hazards regression and cross-validation to evaluate miRNAs and their association with incident MI. We evaluated whether miRNA markers would improve risk classification relative to the Framingham Risk Score. RESULTS: Higher miR-125a-5p and miR-139-5p expression levels were each associated with increased risk of developing MI after adjustment for Framingham Risk Score and HIV-related factors (hazard ratio 2.43, P = 0.018; hazard ratio 2.13, P = 0.048, respectively). Compared with the Framingham Risk Score alone, adding expression levels of miR-125a-5p or miR-139-5p resulted in an integrated discrimination improvement of 10.1 or 5.8%, respectively. CONCLUSION:MiR-125a-5p and miR-139-5p, transcripts known to be differentially expressed in HIV-positive individuals, may serve as unique biomarkers predictive of cardiovascular disease in these patients and may help clarify processes because of HIV infection that contribute to cardiovascular disorders in this population.
Authors: Stephan Fichtlscherer; Salvatore De Rosa; Henrik Fox; Thomas Schwietz; Ariane Fischer; Christoph Liebetrau; Michael Weber; Christian W Hamm; Tino Röxe; Marga Müller-Ardogan; Angelika Bonauer; Andreas M Zeiher; Stefanie Dimmeler Journal: Circ Res Date: 2010-07-01 Impact factor: 17.367
Authors: Virginia A Triant; Jeremiah Perez; Susan Regan; Joseph M Massaro; James B Meigs; Steven K Grinspoon; Ralph B D'Agostino Journal: Circulation Date: 2018-02-14 Impact factor: 29.690
Authors: Bryan Lau; A Richey Sharrett; Larry A Kingsley; Wendy Post; Frank J Palella; Barbara Visscher; Stephen J Gange Journal: Arch Intern Med Date: 2006-01-09
Authors: Jane E Freedman; Mark Gerstein; Eric Mick; Joel Rozowsky; Daniel Levy; Robert Kitchen; Saumya Das; Ravi Shah; Kirsty Danielson; Lea Beaulieu; Fabio C P Navarro; Yaoyu Wang; Timur R Galeev; Alex Holman; Raymond Y Kwong; Venkatesh Murthy; Selim E Tanriverdi; Milka Koupenova-Zamor; Ekaterina Mikhalev; Kahraman Tanriverdi Journal: Nat Commun Date: 2016-04-26 Impact factor: 14.919
Authors: Gloria M Gager; Ceren Eyileten; Marek Postula; Aleksandra Gasecka; Joanna Jarosz-Popek; Georg Gelbenegger; Bernd Jilma; Irene Lang; Jolanta Siller-Matula Journal: Front Cardiovasc Med Date: 2022-07-08
Authors: Brandy E Wade; Kristi M Porter; Sharilyn Almodovar; Justin M Smith; Robert A Lopez-Astacio; Kaiser Bijli; Bum-Yong Kang; Sushma K Cribbs; David M Guidot; Deborah Molehin; Bryan K McNair; Laura Pumarejo-Gomez; Jaritza Perez Hernandez; Ethan A Salazar; Edgar G Martinez; Laurence Huang; Cari F Kessing; Edu B Suarez-Martinez; Kevin Pruitt; Priscilla Y Hsue; William R Tyor; Sonia C Flores; Roy L Sutliff Journal: Sci Rep Date: 2020-07-16 Impact factor: 4.379